McKesson Corporation, a diversified healthcare services company, has signed a definitive agreement to acquire an 80 percent controlling interest in PRISM Vision Holdings for approximately $850 million. PRISM Vision, a provider of ophthalmology and retina management services, will retain a 20 percent ownership stake held by its physicians. McKesson’s CEO, Brian Tyler, stated that the acquisition will strengthen the company’s community practice and specialty solutions, particularly in retinal care. He emphasized that PRISM Vision’s network of over 180 providers, 91 office locations, and 7 ambulatory surgery centers will enhance McKesson’s ability to deliver specialized clinical services, research opportunities, and biopharma partnerships.
Following the acquisition, PRISM Vision will be integrated into McKesson’s U.S. Pharmaceutical segment. The transaction, subject to regulatory approvals, is expected to contribute $0.20 to $0.30 per share to McKesson’s adjusted earnings within the first 12 months, increasing to $0.65 to $0.75 per share by the third year. PRISM Vision’s CEO, Dr. Steven Madreperla, expressed confidence in the partnership, stating, “We are thrilled to be able to bring together PRISM’s exceptional provider base and service delivery platform with McKesson’s deep expertise in care delivery to further develop and expand our eye care network together.” McKesson continues to expand its specialty care capabilities with this acquisition, further supporting physicians and patients in the ophthalmology sector.
